Research Topics
Genomes and Genes | Niels AndreasenSummaryAffiliation: Karolinska Institutet Country: Sweden Publications
| Collaborators
|
Detail Information
Publications
Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markersKhalid Iqbal
New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY 10314, USA
Ann Neurol 58:748-57. 2005..These subgroups, which can be identified by CSF analysis, might benefit differently from different therapeutic drugs...- CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42Niels Andreasen
Karolinska Institute NEUROTEC, Neurotec, Huddinge University Hospital, Sweden
World J Biol Psychiatry 4:147-55. 2003..We stress that the CSF markers should be combined with the clinical information and brain-imaging techniques... - CSF biomarkers for mild cognitive impairment and early Alzheimer's diseaseNiels Andreasen
Karolinska Institutet, Department of Neurotec, Section of Geriatric Medicine, M51, Karolinska University Hospital, Huddinge, SE 141 86 Stockholm, Sweden
Clin Neurol Neurosurg 107:165-73. 2005.... - Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairmentNiels Andreasen
Neurotec, Department of Geriatric Medicine, B84, Huddinge University Hospital, Stockholm, Sweden
Acta Neurol Scand Suppl 179:47-51. 2003..CSF diagnostic markers will be especially important when drugs with potential effects on the progression of AD (e.g. gamma-secretase inhibitors) will reach the clinical phase... 
Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivoTaher Darreh-Shori
Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Karolinska Institutet, Stockholm, Sweden
Neurobiol Aging 32:2320.e15-32. 2011....- Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brainMia E L Blomqvist
Center for Genomics and Bioinformatics, Karolinska Institute, Stockholm, Sweden
Neurobiol Aging 26:795-802. 2005..Results indicate that alleles of IDE contribute to variability in A beta deposition in the AD brain and suggest that this relationship may have relevance for the degree of cognitive dysfunction in AD patients... - Determinants of costs of care for patients with Alzheimer's diseaseLinus Jönsson
Division of Geriatric Epidemiology, The Neurotec Department, Karolinska Institutet, Stockholm, Sweden
Int J Geriatr Psychiatry 21:449-59. 2006..Alzheimer's disease (AD), the most common cause of dementia, is a major cause of disability and care burden in the elderly. This study aims to estimate the costs of formal and informal care and identity determinants of care costs... - Increasing CSF phospho-tau levels during cognitive decline and progression to dementiaChristin Andersson
Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, NOVUM Karolinska University Hospital Huddinge, S 141 86 Stockholm, Sweden
Neurobiol Aging 29:1466-73. 2008..Little is known about longitudinal changes of cerebrospinal fluid (CSF) biomarkers during cognitive decline in neurodegenerative disease progression... - Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's diseaseMaria Eriksdotter-Jonhagen
Departments of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Stockholm, Sweden maria eriksdotter jonhagen ki se
Dement Geriatr Cogn Disord 33:18-28. 2012..Here we report the results of a first-in-man study of encapsulated cell (EC) biodelivery of NGF to the basal forebrain of AD patients with the primary objective to explore safety and tolerability... - Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohortAnders Gustavsson
i3 Innovus, Klarabergsviadukten 90 Hus D, 111 64, Stockholm, Sweden
Eur J Health Econ 13:561-8. 2012..The aim is to estimate prediction models for long-term AD progression and subsequently economic outcomes... - Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's diseaseTaher Darreh-Shori
Division of Alzheimer Neurobiology Center, Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden
J Alzheimers Dis 28:443-58. 2012..APOE4-dependent outcome of BCHE-K genotype as AD risk factor arises through a differential phenotypic modulation of BuChE. Future pharmacogenetic studies should include assessment of the subjects' true phenotypic display of BuChE... 
Dementia management programme in a community setting and the use of psychotropic drugs in the elderly populationErik Jedenius
Department of Neurobiology, Care Sciences and Society, Karolinska Institutet Alzheimer Disease Research Centre, Stockholm, Sweden
Scand J Prim Health Care 29:181-6. 2011..The objective of the present study is to evaluate whether the dementia programme had a secondary effect on the use of psychotropic medication in the elderly population in general...- The cost of diagnosing dementia in a community settingErik Jedenius
Alzheimer s Disease Research Centre, Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Stockholm, Sweden
Int J Geriatr Psychiatry 25:476-82. 2010..Further, in order to establish prerequisites for care and planning it is important to identify the cost of dementia diagnosis. This study aims to evaluate the cost of establishing a dementia diagnosis... - Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's diseaseAhmadul Kadir
Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Sweden
Ann Neurol 63:621-31. 2008.... - Sequence variation in the proximity of IDE may impact age at onset of both Parkinson disease and Alzheimer diseaseMia E L Blomqvist
Center for Genomics and Bioinformatics, Karolinska Institute, Stockholm, Sweden
Neurogenetics 5:115-9. 2004..Results were consistent between AD and PD, suggesting the presence of equivalent detrimental and protective alleles. These data highlight a genomic region in the proximity of IDE that may contribute to AD and PD in a similar manner... - Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human studyBengt Winblad
Karolinska Institutet Alzheimer Disease Research Centre and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden
Lancet Neurol 11:597-604. 2012..We aimed to assess the safety and tolerability of CAD106, a novel active Aβ immunotherapy for patients with Alzheimer's disease, designed to induce N-terminal Aβ-specific antibodies without an Aβ-specific T-cell response... - Amyloid-related biomarkers for Alzheimer's diseaseNiels Andreasen
Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Sweden
Curr Med Chem 15:766-71. 2008.... - A Swedish programme for dementia diagnostics in primary healthcareErik Jedenius
Alzheimer s Disease Research Centre, Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Stockholm, Sweden
Scand J Prim Health Care 26:235-40. 2008..To meet diagnostic needs of dementia, a new care programme was implemented in the county of Kalmar, Sweden. The objective of the study was to analyse whether the programme could identify and diagnose the estimated number of new cases... - Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolismHagit Katzov
Center for Genomics and Bioinformatics, Karolinska Institute, Stockholm, Sweden
Hum Mutat 23:358-67. 2004..Results indicate that variants of ABCA1 may affect the risk of AD, providing further support for a genetic link between AD and cholesterol metabolism... - Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's diseaseNiels Andreasen
Department of Geriatric Medicine, Neurotec, Karolinska Institutet, Huddinge University Hospital, SE 141 86 Stockholm, Sweden
Peptides 23:1205-14. 2002..Recent studies suggest that CSF-Abeta42 have a satisfactory performance when used as a diagnostic marker for AD in clinical routine. This paper reviews CSF-Abeta42 as a biomarker for AD... - Practical lessons from amyloid immunotherapy trials in Alzheimer diseaseAlina Solomon
Aging Research Center ARC, Department of Neurobiology, Care Sciences and Society Karolinska Institutet, Stockholm, Sweden
Curr Alzheimer Res 9:1126-34. 2012..This study investigates practical experiences of staff and participants in immunotherapy RCTs... - The apolipoprotein E ε4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesteraseTaher Darreh-Shori
Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Sweden
Neurobiol Aging 32:1236-48. 2011..In conclusion, ApoE ε4 might impart its pathological role through high protein expression and interaction with BuChE, which in turn might modulate central cholinergic activity and Aβ load in the brain... - Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's DiseaseNiels Andreasen
Memory Clinic, M51, Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, 17176 Stockholm, Sweden
Int J Alzheimers Dis 2010:638379. 2010..Should the two cases have been included and deteriorated, additional investigations might have led to the erroneous conclusion that therapy-induced meningoencephalitis had occurred... - Patient- and proxy-reported utility in Alzheimer disease using the EuroQoLLinus Jönsson
Neurotec, Section for Geriatric Epidemiology, Karolinska Institutet, Stockholm, Sweden
Alzheimer Dis Assoc Disord 20:49-55. 2006..The study shows that the EuroQoL can be used to rate utilities in Alzheimer disease, but there are important differences between patient- and proxy-ratings... - Measurement of Aβ1-42 in cerebrospinal fluid is influenced by matrix effectsJ Randall Slemmon
Discovery Medicine and Clinical Pharmacology, Bristol Myers Squibb Company, Wallingford, Connecticut, USA
J Neurochem 120:325-33. 2012..The data also suggested that denaturation and HPLC of CSF may be a useful approach for studies using Aβ1-42 as a pharmacodynamic marker or in other paradigms where measurement of total non-covalently bound Aβ1-42 is required... - A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsuleBengt Winblad
Karolinska Institutet Alzheimer Research Center, Stockholm, Sweden
Int J Geriatr Psychiatry 22:456-67. 2007..To compare the efficacy, safety and tolerability of a novel rivastigmine transdermal patch with conventional rivastigmine capsules and placebo in patients with Alzheimer's disease (AD)... - Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical settingAsa K Wallin
Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, Malmo, Sweden
Dement Geriatr Cogn Disord 23:150-60. 2007..Clinical short-term trails have shown positive effects of donepezil treatment in patients with Alzheimer's disease. The outcome of continuous long-term treatment in the routine clinical settings remains to be investigated... - Longitudinal stability of CSF biomarkers in Alzheimer's diseaseKaj Blennow
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Molndal, Sweden
Neurosci Lett 419:18-22. 2007.... - Kinesin gene variability may affect tau phosphorylation in early Alzheimer's diseaseMalin E Andersson
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
Int J Mol Med 20:233-9. 2007..018). These findings support earlier indications that genetic variability in the KNS2 gene may play a role during early stages of AD pathogenesis... - Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkersMagnus Sjogren
Institute of Clinical Neuroscience, Goteborg University, SE 431 80, Goteborg, Sweden
Clin Chim Acta 332:1-10. 2003..It increases if P-tau is added. An increasing number of studies suggest that supplementary use of these CSF markers, preferably in combination, adds to the accuracy of an AD diagnosis... - Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodiesHugo Vanderstichele
Innogenetics NV, Industriepark Zwijnaarde 7, 9052 Gent, Belgium
Clin Chem Lab Med 44:1472-80. 2006..Differential diagnosis from dementia with Lewy bodies (DLB) in clinical settings is difficult... - An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluidErik Portelius
Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, University of Goteborg, Sahlgrenska University Hospital, Molndal, Sweden
Neurosci Lett 409:215-9. 2006..Here, we provide direct evidence that an Abeta fragment signature consisting of Abeta1-16, Abeta1-33, Abeta1-39, and Abeta1-42 in CSF distinguishes sporadic AD patients from non-demented controls with an overall accuracy of 86%... - Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231Katharina Buerger
Dementia Research Section and Memory Clinic, Alzheimer Memorial Center, Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig Maximilian University, Nussbaumstrasse 7, 80336 Munich, Germany
Arch Neurol 59:1267-72. 2002.... - Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patientsAnnika Olsson
Institute of Clinical Neuroscience, Experimental Neuroscience Section, Goteborg University, Sahlgrenska University Hospital, Molndal, Sweden
Exp Neurol 183:74-80. 2003..Neither the levels of CSF-beta-sAPP nor CSF-Abeta(42) differed when comparing ApoE4 allele-positive with allele-negative individuals... - Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid studyHarald Hampel
Dementia Research Section and Memory Clinic, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig Maximilian University, Munich, Germany
Arch Gen Psychiatry 61:95-102. 2004..Different tau phosphoepitopes can be sensitively detected in cerebrospinal fluid (CSF)... - Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's diseaseAnnica Johansson
Department of Clinical Neuroscience, Sahlgrenska University Hospital, Goteborg University, Goteborg, Sweden
Hum Genet 114:581-7. 2004..Our results provide an important independent replication of previous findings, supporting the existence of CYP46A1 sequence variants that contribute to variability in beta-amyloid metabolism... - Genetic variation in CTNNA3 encoding alpha-3 catenin and Alzheimer's diseaseMia E-L Blomqvist
Center for Genomics and Bioinformatics, Karolinska Institute, Berzeliusvag 35, S-171 77 Stockholm, Sweden
Neurosci Lett 358:220-2. 2004..More detailed studies of regional linkage disequilibrium structure around CTNNA3 will likely be required to determine whether sequence variation in this region impacts AD... - Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's diseaseHenrik Zetterberg
Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Goteborg University, S 413 45 Gothenburg, Sweden
Neurosci Lett 367:194-6. 2004..35; P = 0.020), although this correlation failed to reach significance in the AD group alone (r = -0.38; P = 0.099). Taken together, the data indicate that TGF-beta1 plays a role in the processes that affect amyloid metabolism in AD... - Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technologyAnnika Olsson
Institute of Clinical Neuroscience, Sahlgrenska University Hospital, Molndal, Sweden
Clin Chem 51:336-45. 2005.... - Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairmentHugo Vanderstichele
Innogenetics NV, Gent, Belgium
Clin Chem 51:1650-60. 2005..CONCLUSION: The CSF markers tau, Abeta42 forms, and P-tau181P, when used as adjuncts to clinical diagnosis, have the potential to help identify AD pathology and could be a valuable asset for early AD diagnosis... - Towards compendia of negative genetic association studies: an example for Alzheimer diseaseMia E-L Blomqvist
Center for Genomics and Bioinformatics, Karolinska Institute, Berzeliusvag 35, 171 77 Stockholm, Sweden
Hum Genet 119:29-37. 2006..By reporting these data we hope to encourage the publication of gene compendia to guide further studies and aid future meta-analyses aimed at resolving the involvement of genes in complex human traits... - The cathepsin D rs17571 polymorphism: effects on CSF tau concentrations in Alzheimer diseaseMatthias Riemenschneider
Neurochemistry and Neurogenetics Laboratory, Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Munich, Germany
Hum Mutat 27:532-7. 2006..The result may corroborate the implication of the lysosomal system in the pathogenesis of AD and is of particular importance if CSF tau is used as a diagnostic biomarker... - Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated formsA M Nilselid
Institute of Clinical Neuroscience, The Sahlgrenska Academy at Goteborg University, Sahlgrenska University Hospital, SE 431 80 Molndal, Sweden
Neurochem Int 48:718-28. 2006..However, the individual clusterin levels overlap between the two groups, and thus cerebrospinal fluid clusterin measurement is not suitable as a biochemical marker in the diagnosis of Alzheimer's disease... - Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteinsPia Davidsson
Department of Clinical Neuroscience, Experimental Neuroscience Section, Goteborg University, Sahlgrenska University Hospital, Molndal, Sweden
Brain Res Mol Brain Res 109:128-33. 2002.... - Altered levels of cerebrospinal fluid reelin in frontotemporal dementia and Alzheimer's diseaseJavier Saez-Valero
Instituto de Neurociencias, UMH CSIC, Campus de San Juan, San Juan, Alicante, Spain
J Neurosci Res 72:132-6. 2003..7 +/- 6.7 arbitrary units; a.u.) and AD (151.4 +/- 3.8 a.u.) compared with control individuals (141.4 +/- 1.2 a.u., P < 0.05). Our results strongly suggest the involvement of reelin signaling in neurodegenerative pathologies... - Cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with Alzheimer's diseaseMaría Salud García Ayllón
Instituto de Neurociencias de Alicante, Universidad Miguel Hernandez CSIC, Sant Joan d Alacant, Spain
J Neurochem 101:1701-11. 2007..The varying responses of different AChE species to ChE-I treatment suggest different modes of regulation, which may have therapeutic implications... - Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's diseaseMaja Puchades
Unit of Experimental Neuroscience, Department of Clinical Neuroscience, Goteborg University, Sahlgrenska University Hospital Molndal, S 431 80 Molndal, Goteborg, Sweden
Brain Res Mol Brain Res 118:140-6. 2003..The levels of 37 proteins spots were altered in AD patients. One of the identified proteins, alpha-2-HS glycoprotein, has not previously been linked to AD. Our study shows that several glycoproteins are altered in AD... - Increased levels of CSF phosphorylated tau in apolipoprotein E epsilon4 carriers with mild cognitive impairmentKatharina Buerger
Dementia Research Section and Memory Clinic, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig Maximilian University, Nussbaumstrasse 7, 80336 Munich, Germany
Neurosci Lett 391:48-50. 2005..Our study indicates that the apoE epsilon4 carrier status should be considered when CSF P-tau(231P) is evaluated as biomarker candidate of AD in MCI subjects... - Common variants of ACE contribute to variable age-at-onset of Alzheimer's diseasePatrick G Kehoe
Department of Care of the Elderly, The John James Building, Frenchay Hospital, University of Bristol, UK
Hum Genet 114:478-83. 2004..These results provide an important complement to existing AD risk data, confirming that ACE harbors sequence variants that contribute to aspects of AD pathology... - Proteome analysis of cerebrospinal fluid proteins in Alzheimer patientsPia Davidsson
Department of Clinical Neuroscience, Experimental Neuroscience Section, , , SE-431 80, Sweden
Neuroreport 13:611-5. 2002..The most prominently altered proteins were the apolipoproteins, especially proapolipoprotein... - Quantitative trait loci in ABCA1 modify cerebrospinal fluid amyloid-beta 1-42 and plasma apolipoprotein levelsHagit Katzov
Centre for Genomics and Bioinformatics, Karolinska Institute, , 171 77 Stockholm, Sweden
J Hum Genet 51:171-9. 2006..Our data illuminate a possible genetic link between Abeta and cholesterol metabolism, but also provide an intriguing example of an environmental exposure that may modify a genotype-phenotype relationship... - The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patientsJin Moo Lee
Division of Laboratory and Genomic Medicine, Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
Clin Chem 54:1617-23. 2008....